{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:01:57Z","timestamp":1791352917123,"version":"4.3.1"},"reference-count":50,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,12,24]],"date-time":"2014-12-24T00:00:00Z","timestamp":1419379200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2014,12,24]],"date-time":"2014-12-24T00:00:00Z","timestamp":1419379200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Motor complications in Parkinson's disease (PD) are associated with long\u2010term oral levodopa treatment and linked to pulsatile dopaminergic stimulation.\n                    <jats:sc>l<\/jats:sc>\n                    \u2010dopa\u2010carbidopa intestinal gel (LCIG) is delivered continuously by percutaneous endoscopic gastrojejunostomy tube (PEG\u2010J), which reduces\n                    <jats:sc>l\u2010<\/jats:sc>\n                    dopa\u2010plasma\u2013level fluctuations and can translate to reduced motor complications. We present final results of the largest international, prospective, 54\u2010week, open\u2010label LCIG study. PD patients with severe motor fluctuations (&gt;3 h\/day \u201coff\u201d time) despite optimized therapy received LCIG monotherapy. Additional PD medications were allowed &gt;28 days post\u2010LCIG initiation. Safety was the primary endpoint measured through adverse events (AEs), device complications, and number of completers. Secondary endpoints included diary\u2010assessed off time, \u201con\u201d time with\/without troublesome dyskinesia, UPDRS, and health\u2010related quality\u2010of\u2010life (HRQoL) outcomes. Of 354 enrolled patients, 324 (91.5%) received PEG\u2010J and 272 (76.8%) completed the study. Most AEs were mild\/moderate and transient; complication of device insertion (34.9%) was the most common. Twenty\u2010seven (7.6%) patients withdrew because of AEs. Serious AEs occurred in 105 (32.4%), most commonly complication of device insertion (6.5%). Mean daily off time decreased by 4.4 h\/65.6% (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001). On time without troublesome dyskinesia increased by 4.8 h\/62.9% (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001); on time with troublesome dyskinesia decreased by 0.4 h\/22.5% (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.023). Improvements persisted from week 4 through study completion. UPDRS and HRQoL outcomes were also improved throughout. In the advanced PD population, LCIG's safety profile consisted primarily of AEs associated with the device\/procedure,\n                    <jats:sc>l\u2010<\/jats:sc>\n                    dopa\/carbidopa, and advanced PD. LCIG was generally well tolerated and demonstrated clinically significant improvements in motor function, daily activities, and HRQoL sustained over 54 weeks. \u00a9 2014 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.\n                  <\/jats:p>","DOI":"10.1002\/mds.26123","type":"journal-article","created":{"date-parts":[[2014,12,24]],"date-time":"2014-12-24T09:44:29Z","timestamp":1419414269000},"page":"500-509","source":"Crossref","is-referenced-by-count":223,"title":["Levodopa\u2010carbidopa intestinal gel in advanced Parkinson's disease: Final 12\u2010month, open\u2010label results"],"prefix":"10.1002","volume":"30","author":[{"given":"Hubert H.","family":"Fernandez","sequence":"first","affiliation":[{"name":"Center for Neurological Restoration Cleveland Clinic Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Standaert","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hauser","sequence":"additional","affiliation":[{"name":"Department of Neurology University of South Florida Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony E.","family":"Lang","sequence":"additional","affiliation":[{"name":"University of Toronto Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor S.C.","family":"Fung","sequence":"additional","affiliation":[{"name":"Movement Disorders Unit Westmead Hospital and Sydney Medical School  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Klostermann","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2010University Medicine Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark F.","family":"Lew","sequence":"additional","affiliation":[{"name":"Keck\/USC School of Medicine Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Odin","sequence":"additional","affiliation":[{"name":"Klinikum\u2010Bremerhaven, Bremerhaven, Germany and Skane University Hospital  Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Steiger","sequence":"additional","affiliation":[{"name":"Walton Center for Neurology and Neurosurgery  Liverpool United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard Z.","family":"Yakupov","sequence":"additional","affiliation":[{"name":"Kazan State Medical University Kazan Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Chouinard","sequence":"additional","affiliation":[{"name":"University of Montreal Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oksana","family":"Suchowersky","sequence":"additional","affiliation":[{"name":"University of Alberta Edmonton Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Dubow","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago  Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coleen M.","family":"Hall","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago  Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krai","family":"Chatamra","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago  Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weining Z.","family":"Robieson","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago  Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet A.","family":"Benesh","sequence":"additional","affiliation":[{"name":"AbbVie Inc., North Chicago  Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto J.","family":"Espay","sequence":"additional","affiliation":[{"name":"University of Cincinnati Academic Health Center Cincinnati Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,12,24]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1159\/000215875"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-010-5741-y"},{"key":"e_1_2_9_4_1","first-page":"335","article-title":"Continuous levodopa for advanced Parkinson's disease","volume":"3","author":"Lundqvist C","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/11310940-000000000-00000"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70521-X"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-013-0981-5"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410250521"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199855001-00001"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23517"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1353-8020(09)70844-2"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241040-00003"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200305000-00010"},{"key":"e_1_2_9_14_1","first-page":"147","article-title":"Continuous intestinal infusion of levodopa\/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection","volume":"27","author":"Abbruzzese G","year":"2012","journal-title":"Funct Neurol"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000149637.70961.4C"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70293-X"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/wnf.0b013e31814b113e"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21500"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000113714"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2009.07.015"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22596"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22450"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2012.11.020"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2007.00818.x"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/08870449708406741"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.69.1.67"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200003000-00003"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23638"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2009.08.016"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21803"},{"key":"e_1_2_9_32_1","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/mds.22130","article-title":"Suicide and death ideation in Parkinson's disease","volume":"23","author":"Nazem S","journal-title":"Mov Disord"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2012.654404"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.06.001"},{"issue":"1","key":"e_1_2_9_35_1","first-page":"402","article-title":"Gastrointestinal safety of the levodopa\u2010carbidopa intestinal gel delivery system in treating advanced Parkinson's patients [abstract]","volume":"28","author":"Epstein M","year":"2013","journal-title":"Mov Disord"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31823a0ee4"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22137"},{"issue":"1","key":"e_1_2_9_38_1","first-page":"403","article-title":"Incidence of peripheral neuropathy in advanced Parkinson's subjects treated with levodopa\u2010carbidopa intestinal gel [abstract]","volume":"28","author":"Freeman R","year":"2013","journal-title":"Mov Disord"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2013.02.006"},{"key":"e_1_2_9_40_1","volume-title":"Summary of product characteristics","author":"Duodopa intestinal gel","year":"2013"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2012.03679.x"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2012.06.022"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060281"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70093-4"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2008.929"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-2011-11037"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2008.01104.x"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2005.078659"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22063"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/124.2.331"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23524"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.26123","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.26123","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.26123","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mds.26123","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.26123","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T13:57:34Z","timestamp":1786629454000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.26123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,24]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1002\/mds.26123"],"URL":"https:\/\/doi.org\/10.1002\/mds.26123","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725290466.793503824","asserted-by":"object"}]},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,24]]}}}